For the roughly 300 million people living with chronic obstructive pulmonary disease worldwide, treatment goals have long focused on symptom relief and exacerbation prevention in isolation. This analysis reframes those targets around a single, composite concept — disease stability — and demonstrates it carries powerful prognostic weight, potentially reshaping how clinicians assess treatment success.
Drawing on post hoc analyses across five Phase 3 randomized trials (IMPACT, FULFIL, MATINEE, METREX, and METREO), researchers defined COPD stability as the simultaneous absence of moderate-to-severe exacerbations combined with no deterioration in both the COPD Assessment Test (CAT) score and FEV1 from baseline. Achievement rates varied considerably by regimen: 22% of patients on triple therapy (fluticasone furoate/umeclidinium/vilanterol) attained stability at week 52 in IMPACT, compared with 46% at week 24 in FULFIL. Mepolizumab added onto triple therapy achieved stability in 18% of patients across MATINEE/METREX/METREO. Crucially, patients who achieved stability by week 28 showed a 45.7% lower subsequent risk of moderate-to-severe exacerbations and a 51.7% reduction in all-cause mortality risk compared with unstable counterparts — findings supported by Bayesian joint modeling.
The composite endpoint concept here is methodologically significant. COPD trials have historically used exacerbation rates or lung function as siloed endpoints, which can miss patients who stabilize on one dimension while worsening on another. Defining stability as a multidimensional low-disease-activity state — borrowed conceptually from rheumatology frameworks like treat-to-target — represents a meaningful evolution in trial design philosophy. That said, important caveats apply: these are post hoc, not pre-specified analyses, meaning they carry heightened risk of selection bias and cannot establish causality. The relatively low stability achievement rates (18–46%) also underscore that even optimized triple therapy leaves most COPD patients in a suboptimal disease state. Whether this composite endpoint will be adopted as a prospective primary outcome in future trials remains to be seen, but the mortality signal is striking enough to merit serious attention.